IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

被引：0

作者：

Eraslan, Lale Erdem ^{[1
]}

van den Bent, Martin ^{[1
]}

Kros, Johan ^{[1
]}

Oosterkamp, Hendrika ^{[2
]}

Walenkamp, Annemiek ^{[3
]}

Beerepoot, Laurens ^{[4
]}

Hanse, Monique ^{[5
]}

Buter, J. ^{[6
]}

Honkoop, Aafke ^{[7
]}

van der Holt, Bronno ^{[1
]}

Vernhout, R. M. ^{[1
]}

Smitt, Peter Sillevis ^{[1
]}

Taal, Walter ^{[1
]}

French, Pim ^{[1
]}

机构：

[1] Erasmus MC, Rotterdam, Netherlands

[2] MC Haaglanden, The Hague, Netherlands

[3] Univ Med Ctr Groningen, Groningen, Netherlands

[4] Elisabeth Hosp, Tilburg, Netherlands

[5] Catharina Hosp, Eindhoven, Netherlands

[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[7] Isala Klin, Zwolle, Netherlands

来源：

NEURO-ONCOLOGY | 2014年 / 16卷

关键词：

D O I：

10.1093/neuonc/nou256.10

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

GE-10

引用

页数：1

共 50 条

[1] IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB
French, Pim
Erdem-Eraslan, L.
Kros, J. M.
Oosterkamp, H. M.
Walenkamp, A. M. E.
Beerepoot, L.
Hanse, M.
Buter, J.
Honkoop, A.
van der Holt, B.
Vernhout, R. M.
Smitt, P. A. E. Sillevis
Taal, W.
van den Bent, M. J.
NEURO-ONCOLOGY, 2014, 16
[2] Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM)
Raval, Sumul N.
Rule, Amy
Hwang, Shirley S.
NEURO-ONCOLOGY, 2006, 8 (04) : 482 - 482
[3] Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
Raval, S.
Hwang, S.
Dorsett, L.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[4] Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
Erdem-Eraslan, Lale
van den Bent, Martin J.
Hoogstrate, Youri
Naz-Khan, Hina
Stubbs, Andrew
van der Spek, Peter
Bottcher, Rene
Gao, Ya
de Wit, Maurice
Taal, Walter
Oosterkamp, Hendrika M.
Walenkamp, Annemiek
Beerepoot, Laurens V.
Hanse, Monique C. J.
Buter, Jan
Honkoop, Aafke H.
van der Holt, Bronno
Vernhout, Rene M.
Smitt, Peter A. E. Sillevis
Kros, Johan M.
French, Pim J.
CANCER RESEARCH, 2016, 76 (03) : 525 - 534
[5] Identifying factors to predict benefit from bevacizumab in progressive glioblastoma multiforme (GBM).
Gleeson, Jack Patrick
Alhusaini, Abdullah
O'Halloran, Philip
Harrold, Emily
Keegan, Niamh M.
Karadawi, Nabeeha Eltag
Mammadov, Emin
Kamel, Dalia
Egan, Keith
Molloy, Susan
Hennessy, Bryan T.
Breathnach, Oscar S.
Grogan, William
Morris, Patrick G.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[6] Radiographic evaluation of recurrent glioblastoma multiforme (GBM) in patients treated with bevacizumab and irinotecan
Andre, J.
Spearman, K.
Lu, S.
Hwang, S.
Dorsett, L.
Raval, S.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[7] Radiographic evaluation of recurrent glioblastoma multiforme (gbm) in patients treated with bevacizumab and irinotecan
Andre, Jalal
Spearman, Kenneth
Lu, Stanley
Raval, Sumul
NEURO-ONCOLOGY, 2007, 9 (04) : 575 - 575
[8] BEVACIZUMAB IN REAL LIFE PATIENTS WITH RECURRENT GLIOBLASTOMA: BENEFIT OR FUTILITY?
Smolenschi, Cristina
Colomba, Emeline
Rassy, Elie
Lezghed, Naima
Kettab, Mohamed
Louvel, Guillaume
Garcia, Gabriel
Cheaib, Bianca
Bockel, Sophie
Pallud, Johan
Dezamis, Edouard
Copaciu, Razvan
Knafo, Steven
Ammari, Samy
Dhermain, Frederic
Domont, Julien
Martanovschi, Larisa
Mahmoud, Fekih
Dumont, Sarah
NEURO-ONCOLOGY, 2020, 22 : 133 - 133
[9] BENEFIT OF BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA. RESULTS OF 81 PATIENTS FROM A SINGLE INSTITUTION
Absalyamova, O.
Kobiakov, G.
Agabekyan, G.
Poddubsky, A.
Belyashova, A.
Lodygina, K.
Absalyamov, A.
Kobiakov, N.
NEURO-ONCOLOGY, 2019, 21 : 69 - 69
[10] Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)
Maron, R.
Vredenburgh, J. J.
Desjardins, A.
Reardon, D. A.
Quinn, J. A.
Rich, J. N.
Gururangan, S.
Wagner, S. A.
Salacz, M. E.
Friedman, H. S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →